About Sania
Sania is a company based in New York (United States) founded in 2020 by Rob Brownstone, Raj S Dattani, and Andy Murray. Sania has raised $11.55 million across 3 funding rounds. The company has 5 employees. Sania offers products and services including Precision Therapies. Sania operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Vir Biotechnology, Neurocrine and PTC Therapeutics, among others.
- Headquarter New York, United States
- Employees 5
- Founders Rob Brownstone, Raj S Dattani, Andy Murray
- SectorsHealthcare
- Website saniarx.com
- Social LinkedIn X
- Legal Name Sania Therapeutics, Inc.
- Total Equity Funding$11.55M (USD)
in 3 rounds
- Latest Funding Round$5M (USD), Series B
May 2024
- Employee Count5
Products & Services of Sania
Sania offers a comprehensive portfolio of products and services, including Precision Therapies.
Therapies that target delivery for treating nervous system disorders.
Funding Insights of Sania
Sania has successfully raised a total of $11.55M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.55M
- Total Rounds 3
- Last Round Series B — $5M
- First Round $5.05M
(Mar 2022)
All 3 funding rounds of Sania with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $5M | Series B | – | – | – |
| Mar 2023 | $1.5M | Series A | – | – | – |
| Mar 2022 | $5.05M | Series A | – | – | – |
People of Sania
3 people are tracked at Sania (3 in leadership); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Rob Brownstone | Co-Founder | Leadership |
Raj S Dattani | Co-Founder | Leadership |
Andy Murray | Co-Founder & CEO | Leadership |
Complete people profiles for Sania
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sania
3 dated milestones of Sania across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Sania is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series B, of $5.0M.
Competitors of Sania
Sania operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Vir Biotechnology, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. |
Detailed competitors of Sania
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sania
The website of Sania (saniarx.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 39.8% vs previous month
Latest news on Sania
Complete news archive for Sania
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sania
10 companies that operate in the same segment as Sania (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sania
Sania was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Sania is headquartered in New York, United States. It is registered at New York, New York, United States.
Andy Murray is the current CEO of Sania. They have also founded this company.
Sania is a funded company, having raised a total of $11.55M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5.05M, raised on Mar 2022.
Sania has 5 employees.
Founded in 2020 and based in New York, United States, gene therapies targeting neurological diseases are developed. Operations center on next-generation vectors, including engineered adeno-associated viruses (AAVs), designed to address malfunctioning neural circuits. The biotech sector focus involves creating treatments for conditions affecting the nervous system, with activities conducted through research and vector engineering processes.
Sania's top competitors include Jazz Pharmaceuticals, Vaxcyte and PTC Therapeutics.
Sania offers Precision Therapies.
Sania operates through Sania Therapeutics, Inc..